Company Overview of aTyr Pharma Inc.
aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
Total Annual Compensation: $410.0K
President and Chief Operating Officer
Total Annual Compensation: $319.7K
Chief Medical Officer
Total Annual Compensation: $265.2K
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Inc.(NasdaqGS:LIFE) added to NASDAQ Composite Index
May 8 15
aTyr Pharma Inc. has been added to Nasdaq Composite Index.
aTyr Pharma Appoints Marcy Graham as Vice President, Investor Relations and Corporate Communications
Apr 9 15
aTyr Pharma announced that it has named Marcy Graham as Vice President, Investor Relations and Corporate Communications. Ms. Graham was previously Executive Director of Investor Relations and Corporate Communications at Ambit Biosciences, where she built the company's investor relations program from their initial public offering to their eventual acquisition. In her role at aTyr, Ms. Graham will spearhead investor relationship management while positioning the company as a global leader in the development of Physiocrine-based medicines to address severe, rare diseases.
aTyr Pharma Seeks Acquisitions
Apr 6 15
aTyr Pharma Inc. announced an initial public offering of its common stocks and said that, "We may also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products, or assets. Although we have no specific agreements, commitments, or understandings with respect to any in-license or acquisition."
Similar Private Companies By Industry
Recent Private Companies Transactions
March 31, 2015
Most Searched Private Companies
Sponsored Financial Commentaries